Rituximab and DexaBEAM as Salvage Therapy for Relapsed Lymphoma

PHASE2CompletedINTERVENTIONAL
Enrollment

103

Participants

Timeline

Start Date

May 31, 2001

Primary Completion Date

May 31, 2005

Study Completion Date

March 31, 2014

Conditions
Relapsed Non-Hodgkin-Lymphoma
Interventions
DRUG

Rituximab and DexaBEAM

combination treatment

All Listed Sponsors
collaborator

Roche Pharma AG

INDUSTRY

collaborator

Klinikum Frankfurt Höchst

OTHER

lead

Georg Hess, MD

OTHER

NCT02099292 - Rituximab and DexaBEAM as Salvage Therapy for Relapsed Lymphoma | Biotech Hunter | Biotech Hunter